DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, November 22, 2022

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022. Daniel Tassé, Chief Executive Officer, will participate in a Fireside Chat session on Wednesday, Nov. 30, at 8 a.m. ET, as well as one-on-one investor meetings throughout the day.

A live webcast of the fireside chat will be available on the Investors & Media section of the Company’s website: https://wsw.com/webcast/evercore29/dbvt/2371680.

A replay will also be available on DBV Technologies’ website for 90 days after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

56 minutes ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

56 minutes ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

56 minutes ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

56 minutes ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

56 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

56 minutes ago